GelStat Corporation (GSAC) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, GelStat Corporation (GSAC) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 65/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026GelStat Corporation (GSAC) Resumen de Asistencia Médica y Tuberías
GelStat Corporation operates in the consumer healthcare sector, developing and marketing over-the-counter products like GelStat Migraine and Chews 2 Lose. With a small team and focus on non-prescription solutions, the company faces competition from larger generic drug manufacturers and established consumer health brands in a fragmented market.
Tesis de Inversión
GelStat Corporation presents a high-risk, high-reward investment profile. The company's small market capitalization and limited resources make it vulnerable to market fluctuations and competitive pressures. A potential upside lies in the successful commercialization of its existing product line and the development of new OTC products. With a negative P/E ratio of -3.37 and a negative profit margin of -73.3%, the company's financial performance needs significant improvement. The company's beta of 1.26 indicates higher volatility compared to the market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company with limited financial resources and a concentrated product portfolio.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.00B reflects the company's small size and limited market presence.
- P/E Ratio of -3.37 indicates the company is currently not profitable.
- Profit Margin of -73.3% highlights significant challenges in achieving profitability.
- Gross Margin of 70.3% suggests potential for profitability if operating expenses are managed effectively.
- Beta of 1.26 indicates higher volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Patented GelStat Migraine formula.
- Established distribution network.
- Focus on over-the-counter products.
- Gross margin of 70.3% indicates potential profitability.
Debilidades
- Small market capitalization.
- Limited financial resources.
- Negative profit margin.
- High dependence on a few key products.
Catalizadores
- Upcoming: Potential FDA approval for new OTC products in development.
- Ongoing: Expansion of distribution network to new retailers and wholesalers.
- Ongoing: Increased marketing efforts to drive product awareness and sales.
Riesgos
- Potential: Intense competition from larger pharmaceutical companies.
- Potential: Stringent regulatory requirements and potential product recalls.
- Ongoing: Limited financial resources and potential need for additional funding.
- Ongoing: Dependence on a few key products and potential for declining sales.
- Potential: Product liability claims and associated legal expenses.
Oportunidades de crecimiento
- Expansion of Product Line: GelStat can expand its product line by developing new OTC products targeting specific health concerns. The market for OTC products is vast, with opportunities in areas such as pain management, digestive health, and immune support. Successful development and launch of new products could drive revenue growth and increase market share. The timeline for this growth opportunity depends on the company's ability to secure funding for R&D and navigate regulatory approval processes.
- Strategic Partnerships: GelStat can pursue strategic partnerships with larger pharmaceutical companies or distributors to expand its market reach and access new distribution channels. Collaborations could provide access to established sales networks and marketing resources, accelerating product adoption and revenue growth. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
- E-commerce Expansion: GelStat can invest in expanding its e-commerce presence to reach a wider customer base and capitalize on the growing trend of online shopping. Developing a user-friendly online platform and implementing effective digital marketing strategies could drive online sales and increase brand awareness. The timeline for this growth opportunity depends on the company's ability to invest in technology and digital marketing resources.
- Geographic Expansion: GelStat can explore opportunities to expand its geographic reach by entering new markets outside of the United States. International expansion could provide access to new customer segments and diversify revenue streams. The timeline for this growth opportunity depends on the company's ability to navigate international regulatory requirements and establish distribution networks in new markets.
- Focus on Niche Markets: GelStat can focus on developing and marketing products for niche markets with specific health needs. By targeting underserved segments of the population, the company can differentiate itself from larger competitors and build a loyal customer base. The timeline for this growth opportunity depends on the company's ability to identify and understand the needs of specific niche markets.
Oportunidades
- Expansion of product line.
- Strategic partnerships with larger companies.
- E-commerce expansion.
- Geographic expansion into new markets.
Amenazas
- Intense competition from larger companies.
- Stringent regulatory requirements.
- Changing consumer preferences.
- Potential product liability claims.
Ventajas competitivas
- Patented GelStat Migraine formula provides some protection.
- Established relationships with retailers and distributors.
- Brand recognition among consumers seeking specific OTC solutions.
Acerca de GSAC
GelStat Corporation, headquartered in Palm City, Florida, is a consumer healthcare company engaged in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's portfolio includes GelStat Migraine, a patented product designed to provide pain relief from migraine headaches. Other products include Chews 2 Lose, an appetite suppressant gum intended as a diet aid; All Natural Speed, an energy supplement; and GelStat Sleep, a product formulated to alleviate sleep disorders and associated symptoms. GelStat Corporation distributes its products through a network of retailers, wholesalers, specialty distributors, and catalog merchandisers, utilizing both direct sales and external sales brokers. Founded with the aim of providing accessible consumer health solutions, GelStat Corporation has focused on developing and commercializing products that address common health concerns. The company's strategy involves identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription. Despite its efforts, the company faces challenges in a competitive market dominated by larger players with greater resources and established brand recognition.
Qué hacen
- Researches and develops over-the-counter (OTC) healthcare products.
- Markets and sells non-prescription consumer health products.
- Offers GelStat Migraine for migraine pain relief.
- Provides Chews 2 Lose appetite suppressant gum.
- Sells All Natural Speed energy supplements.
- Offers GelStat Sleep for relief from sleep disorders.
- Distributes products through retailers, wholesalers, and distributors.
Modelo de Negocio
- Develops and patents over-the-counter healthcare products.
- Manufactures or outsources the production of its products.
- Sells products directly to retailers, wholesalers, and distributors.
- Generates revenue through product sales.
Contexto de la Industria
GelStat Corporation operates within the competitive and highly regulated drug manufacturers - specialty & generic industry. This sector is characterized by intense competition, stringent regulatory requirements, and evolving consumer preferences. The market for over-the-counter (OTC) drugs and non-prescription healthcare products is substantial, driven by increasing consumer awareness and a desire for self-care solutions. However, companies like GelStat face challenges from larger, more established players with greater resources and broader distribution networks. The industry is also subject to regulatory scrutiny from agencies like the FDA, which impacts product development, manufacturing, and marketing activities.
Clientes Clave
- Retailers selling OTC healthcare products.
- Wholesalers distributing healthcare products.
- Specialty distributors focusing on specific product categories.
- Consumers seeking non-prescription health solutions.
Finanzas
Gráfico e información
Precio de la acción de GelStat Corporation (GSAC): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para GSAC.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GSAC.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GSAC.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GSAC en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Javier G. Acosta
CEO
Javier G. Acosta serves as the CEO of GelStat Corporation. Information regarding his detailed career history and educational background is not available in the provided data. As the managing executive of a small team of two employees, Acosta's role likely involves overseeing all aspects of the company's operations, from product development and marketing to sales and distribution. His leadership is critical to the company's ability to navigate the competitive consumer healthcare market and achieve its strategic goals.
Historial: Due to the limited information available, it is difficult to assess Javier G. Acosta's specific track record at GelStat Corporation. However, as CEO, he is responsible for guiding the company's strategic direction and overseeing its day-to-day operations. Key milestones under his leadership would include product launches, distribution agreements, and any improvements in the company's financial performance. The success of GelStat Migraine and other OTC products would be indicators of his leadership effectiveness.
Información del mercado OTC de GSAC
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no reporting requirements, meaning they may not be required to file financial statements with the SEC. This lack of transparency increases the risk for investors, as there is less information available to assess the company's financial health and operations. Companies in this tier are often speculative and may be subject to significant price volatility.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited or no financial reporting requirements.
- Lack of regulatory oversight.
- High potential for fraud and manipulation.
- Significant price volatility.
- Illiquidity and difficulty in buying or selling shares.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Determine if the company is subject to SEC reporting requirements.
- Company has been in operation for several years.
- Company has a patented product (GelStat Migraine).
- Company has established relationships with retailers and distributors.
- Company has a functional website and contact information.
- Company's products are available for sale through various channels.
GSAC Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar GSAC?
GelStat Corporation (GSAC) actualmente tiene una puntuación IA de 65/100, indicando puntuación moderada. Fortaleza clave: Patented GelStat Migraine formula.. Riesgo principal a monitorear: Potential: Intense competition from larger pharmaceutical companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GSAC?
GSAC actualmente puntúa 65/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GSAC?
Los precios de GSAC se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GSAC?
La cobertura de analistas para GSAC incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GSAC?
Las categorías de riesgo para GSAC incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from larger pharmaceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GSAC?
La relación P/E para GSAC compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GSAC sobrevalorada o infravalorada?
Determinar si GelStat Corporation (GSAC) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GSAC?
GelStat Corporation (GSAC) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on the company's financial performance and operations.
- OTC listing increases the risk of investing in GSAC.
- Analyst coverage is not available for GSAC.